Sonntag, 19. April 2026

The Daily

Sunday shape, frische Luft und ein paar gute Umwege.

Wien heute: ⛅ +7 °C am frühen Morgen. Kühl, ruhig, gut für einen langen Start in den Sonntag.

🏀 NBA

The bracket is finally real, and today is about texture more than picks

This is the first full playoff Sunday that feels settled enough to read as basketball instead of administrative sorting. Today’s card brings Bucks-Pacers, Clippers-Nuggets, Pistons-Knicks and Wolves-Lakers, which is a useful mix of old grudges, awkward pressure and teams trying to prove that regular-season identities survive the postseason. Milwaukee and Indiana still carry last year’s irritation into a new series. Denver gets the familiar question of whether Nikola Jokić can drag a title ceiling back into view. New York opens under the heavier kind of expectation, the kind that changes how every quarter feels. And Lakers-Wolves is the glamour matchup, but also the one with the cleanest stylistic tension. At this stage the interesting move is not to guess the endings. It is to notice which teams arrive with a repeatable shape, and which ones still look like they are borrowing certainty game by game.

Source: Fritz

The Athletic’s first-round map is best when it follows pressure points

The big preview package is strongest where it treats each series as an organizational stress test, not just a matchup table. That is especially true for the Knicks, Cavs and Thunder tiers of expectation.

Source: NYT / The Athletic

The league’s own Sunday framing is built around rivalry, stamina and star burden

NBA.com’s morning package is a useful spoiler-safe guide to the day because it stays on matchup texture, availability and broader stakes. For today, that is exactly enough.

Source: NBA.com

This postseason may be less chalky than the seeding suggests

A broader Athletic preview argues that recent playoff history has been unusually kind to teams without home-court advantage. That makes this bracket feel less hierarchical and more volatile than the numbers imply.

Source: NYT / The Athletic


Wien – Kultur & Essen

Der Vienna City Marathon macht Wien heute eher lesbar als chaotisch

FALTER hat die nützliche Sonntagsversion des Marathon-Themas: nicht Pathos, sondern was die Stadt heute praktisch verändert. 49.000 Anmeldungen bedeuten Rekord, dazu kommen Sperren vom Ring bis zur Praterstraße, verdichtete U-Bahn-Intervalle und ein Tagesrhythmus, der Wien für ein paar Stunden anders sortiert. Für Robert ist das weniger Sportstory als Stadtstory.

Source: FALTER

Voodoo Jürgens spricht so gut über Haltung wie andere über Image

The FALTER interview around “Gschnas” is not just album promo. It works because Jürgens stays close to the Viennese worlds he sings about without turning them into costume.

Source: FALTER

Das Porn Film Festival startet politischer, als sein Name vermuten lässt

Im Wien-Newsletter rahmt FALTER das Festival nicht als Gag, sondern als Debatte über Blick, Macht und Öffentlichkeit. Genau deshalb ist es ein brauchbarer Wien-Tipp.

Source: FALTER

Rote Emma in Kagran klingt nach Wohnbau, aber die interessante Frage ist Stadtgefühl

FALTERs Architekturkritik hebt das Projekt aus der Förderlogik heraus und fragt, was an so einem Bau wirklich urban wirkt. Das ist die nützlichere Linse als bloß Quadratmeter und Fassadenlob.

Source: FALTER


Biotech & Pharma

2026 is starting to look like the year biotech M&A turns normal again

FT’s pharmaceuticals coverage points to a better capital mood than the sector had last year, with large pharma again willing to shop for pipeline rather than wait for perfect certainty. That matters because oncology-heavy biotech has spent a long time proving science while markets kept discounting the bridge to exit. If deal appetite is broadening, late-clinical names may stop being priced like stranded assets.

Source: FT

A China-licensed GSK cancer drug is drawing exactly the kind of attention big pharma wanted

FT’s biotech feed flags promising trial results for a GSK oncology asset sourced from China. The subtext is now familiar and important: licensing from China is no longer edge behavior, it is core pipeline strategy.

Source: FT

Psychedelic medicine just got a real regulatory tailwind

Separate from the politics, the NYT story matters as a drug-development signal. A federal push to ease research restrictions and fund ibogaine work changes timelines, investor interest and trial feasibility.

Source: NYT

Keytruda shows how a clinical breakthrough can become a system-level cost problem

SPIEGEL’s Keytruda piece is worth reading because it keeps both truths in frame: immunotherapy can be transformative for patients, and still test the financing logic of a public health system.

Source: Spiegel+


OpenClaw

The latest pre-release is mostly about making multi-agent behavior less weird

The fresh GitHub release is not flashy, but it is good operator work. The most useful fixes tighten session routing, subagent account binding and Telegram callback handling, which means fewer invisible failures in shared rooms and fewer cases where the system looks alive while a control path is actually wedged.

Source: GitHub Releases

Release channels are now clear enough to use on purpose

The development-channels doc finally makes stable, beta and dev feel operational rather than tribal. The useful bit is the fallback behavior, especially how beta can fall back to stable when needed.

Source: OpenClaw Docs

A new auth-status card pushes model health closer to the surface

One of the stronger April changes is the Model Auth overview card. It turns expiring OAuth and rate-limit pressure into something operators can actually spot before a session goes strange.

Source: GitHub Releases

Memory is getting more durable and a little less noisy

Cloud storage support for memory-lancedb and the shift toward separate dreaming storage both point the same way: memory that scales better and pollutes daily context less.

Source: GitHub Releases